Harmony Biosciences Holdings Inc (HRMY)

Citi on Harmony (HRMY): 'FDA Denies Short Seller Citizens' Petition to Remove Wakix from the Market, Ending ... - StreetInsider.com

StreetInsider.com

Harmony Biosciences Says FDA Denies Short Seller Claims Over Narcolepsy Drug Safety - MarketWatch

MarketWatch

Harmony Biosciences (HRMY) Acknowledges FDA Action Denying The Citizen Petition For Wakix - StreetInsider.com

StreetInsider.com

Harmony Biosciences Holdings, Inc. Announces U.S. Food & Drug Administration Action Deny the Citized Petition for ... - Marketscreener.com

Marketscreener.com

Los Angeles Capital Management LLC Purchases 1076 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ ... - Defense World

Defense World

Harmony Biosciences (NASDAQ:HRMY) Receives “Buy” Rating from Needham & Company LLC - Defense World

Defense World

Harmony Biosciences maintains $56 target with Outperform rating - Investing.com India

Investing.com India

Harmony Biosciences maintains $56 target with Outperform rating By Investing.com - Investing.com

Investing.com

Harmony Biosciences maintains $56 target with Outperform rating By Investing.com - Investing.com UK

Investing.com UK

Wakix approval boosts Harmony Biosciences outlook By Investing.com - Investing.com Australia

Investing.com Australia

Wakix approval boosts Harmony Biosciences outlook By Investing.com - Investing.com Canada

Investing.com Canada

Wakix approval boosts Harmony Biosciences outlook - Investing.com India

Investing.com India

Silence Therapeutics receives $2 million from Hansoh Pharma By Investing.com - Investing.com

Investing.com

Harmony Biosciences (NASDAQ:HRMY) Earns Buy Rating from Needham & Company LLC - MarketBeat

MarketBeat

Oppenheimer on Harmony Biosciences Holdings Inc. (HRMY): 'WAKIX Approved for EDS in Pediatric Narcolepsy ... - StreetInsider.com

StreetInsider.com

HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX ... - PR Newswire

PR Newswire

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX in Pediatric Patients with ... - Marketscreener.com

Marketscreener.com

Harmony Biosciences (NASDAQ:HRMY) Shares Gap Up to $28.81 - Defense World

Defense World

Citigroup Initiates Coverage of Harmony Biosciences Holdings (HRMY) with Buy Recommendation - MSN

MSN

(HRMY) Long Term Investment Analysis - Stock Traders Daily

Stock Traders Daily

Harmony Bio gains as Citi starts at Buy on risk-reward setup - MSN

MSN

Harmony Biosciences (NASDAQ:HRMY) Receives New Coverage from Analysts at Citigroup - MarketBeat

MarketBeat

A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts - Markets Insider

Markets Insider

Harmony Biosciences (NASDAQ:HRMY) Coverage Initiated at Citigroup - Defense World

Defense World

A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts - Harmony Biosciences (NASDAQ ... - Benzinga

Benzinga

Harmony Biosciences (NASDAQ:HRMY) Shares Gap Up to $28.81 - MarketBeat

MarketBeat

Harmony Bio stock gains as Citi starts at Buy(NASDAQ:HRMY) - Seeking Alpha

Seeking Alpha

Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains? - Yahoo Finance

Yahoo Finance

Citi sets Harmony Biosciences stock to buy with $48 target By Investing.com - Investing.com

Investing.com

Citigroup Initiates Coverage of Harmony Biosciences Holdings (HRMY) with Buy Recommendation - MSN

MSN

Citi sets Harmony Biosciences stock to buy with $48 target By Investing.com - Investing.com

Investing.com

Harmony Biosciences Holdings Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle

The InvestChronicle

Obesity Market to Observe Impressive Growth by 2034, Assesses DelveInsight | Key Companies - Novo Nordisk A/S ... - Yahoo Finance

Yahoo Finance

Brokerages Set Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Target Price at $40.63 - Defense World

Defense World

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

MarketBeat

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

Defense World

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

Defense World

Harmony Biosciences Presents Promising Data on Pitolisant for Myotonic Dystrophy Type 1 - MyChesCo

MyChesCo

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Holdings Boosted by Campbell & CO Investment Adviser LLC - Defense World

Defense World

Harmony Biosciences Presents Promising Data on Pitolisant for Myotonic Dystrophy Type 1 - MyChesCo

MyChesCo

Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Simply Wall St

Simply Wall St

Franklin Resources Inc. Acquires New Stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat

MarketBeat

Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Stock Has Fared Decently: Is the Market Following Strong ... - Yahoo Canada Sports

Yahoo Canada Sports

Franklin Resources Inc. Acquires Shares of 27136 Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World

Defense World

Harmony releases promising phase 2 results of pitolisant for myotonic dystrophy - Seeking Alpha

Seeking Alpha

HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE ... - Quantisnow

Quantisnow

HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE ... - Marketscreener.com

Marketscreener.com

HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE ... - PR Newswire

PR Newswire

HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE ... - PR Newswire

PR Newswire

HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE ... - Quantisnow

Quantisnow